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Abstract
Background: Constipation affects up to 20% of adults. Chronic constipation (CC) affects 1–2% of adults. Patient
dissatisfaction is high; nearly 80% feel that laxative therapy is unsatisfactory and symptoms have significant impact
on quality of life. There is uncertainty about the value of specialist investigations and whether equipment-intensive
therapies using biofeedback confer additional benefit when compared with specialist conservative advice.
Methods/design: A three-arm, parallel-group, multicentre randomised controlled trial.
Objectives: to determine whether standardised specialist-led habit training plus pelvic floor retraining using
computerised biofeedback is more clinically effective than standardised specialist-led habit training alone; to
determine whether outcomes are improved by stratification based on prior investigation of anorectal and colonic
pathophysiology. Primary outcome measure is response to treatment, defined as a 0.4-point (10% of scale) or
greater reduction in Patient Assessment of Constipation–Quality of Life (PAC-QOL) score 6 months after the end of
treatment. Other outcomes up to 12 months include symptoms, quality of life, health economics, psychological
health and qualitative experience.
Hypotheses: (1) habit training (HT) with computer-assisted direct visual biofeedback (HTBF) results in an average
reduction in PAC-QOL score of 0.4 points at 6 months compared to HT alone in unselected adults with CC, (2)
stratification to either HT or HTBF informed by pathophysiological investigation (INVEST) results in an average 0.4-
point reduction in PAC-QOL score at 6 months compared with treatment not directed by investigations (No-
INVEST).
Inclusion: chronic constipation in adults (aged 18–70 years) defined by self-reported symptom duration of more
than 6 months; failure of previous laxatives or prokinetics and diet and lifestyle modifications. Consenting
participants (n = 394) will be randomised to one of three arms in an allocation ratio of 3:3:2: [1] habit training, [2]
habit training and biofeedback or [3] investigation-led allocation to one of these arms. Analysis will be on an
intention-to-treat basis.
Discussion: This trial has the potential to answer some of the major outstanding questions in the management of
chronic constipation, including whether costly invasive tests are warranted and whether computer-assisted direct
visual biofeedback confers additional benefit to well-managed specialist advice alone.
Trial registration: International Standard Randomised Controlled Trial Number: ISRCTN11791740. Registered on 16
July 2015.
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Background
Constipation is common in adults and children and up
to 20% of the population report this symptom depending
on definitions used (2–28% adults; 0.7–30% children)
[1–3], with a higher prevalence in women [1, 4, 5] and
older people [6, 7]. Chronic constipation (CC), usually
defined as more than 6 months of symptoms, is less
common [8] but results in 0.5 million UK GP consulta-
tions per annum. A proportion of the population suffer
symptoms which are both chronic and disabling (ap-
proximately 1–2% of the population) [9]. Such patients,
who are very frequently female [10], are usually referred
to secondary care with many progressing to tertiary spe-
cialist investigation. Patient dissatisfaction is high in this
group; nearly 80% feel that laxative therapy is unsatisfac-
tory [11] and the effect of symptoms on quality of life
(QOL) is significant [12]. Constipation consumes signifi-
cant health care resources. In the US in 2012, a primary
complaint of constipation was responsible for 3.2 million
physician visits [13] resulting in (direct and indirect)
costs of US$1.7 billion. In the UK, it is estimated 10% of
district nursing time is spent on constipation [14] and
the annual spend on laxatives exceeds £80 million, with
17.4 million medication prescriptions in 2012 [15].
The act of defaecation is dependent on the coordi-
nated functions of the colon, rectum and anus. Consid-
ering the complexity of neuromuscular (sensory and
motor) functions required to achieve planned, conscious
and effective defaecation [16] it is no surprise that dis-
turbances to perceived ‘normal’ function occur com-
monly at all stages of life. Clinically, such problems
often lead to symptoms of obstructed defaecation, e.g.
straining; incomplete, unsuccessful or painful evacu-
ation; bowel infrequency; abdominal pain and bloating.
After exclusion of a multitude of possible secondary
causes (obstructing colonic lesions, neurological, meta-
bolic and endocrine disorders), the pathophysiology of
CC can broadly be divided into problems of colonic con-
tractile activity (and hence stool transit) and problems of
evacuation and the pelvic floor. Thus, with specialist
physiological investigation (hereafter referred to as IN-
VEST in this protocol), patients may be divided into
those who have slow colonic transit, evacuation disorder,
both or neither (no abnormality found with tests).
Evacuation disorders can be then subdivided into those
in whom a structurally significant pelvic floor abnormal-
ity is evident, e.g. rectocoele or internal prolapse (intus-
susception) and those in whom there is a dynamic
failure of evacuation without structural abnormality:
most commonly termed ‘functional defaecation disorder’
(FDD).
Management of CC is a major problem due to its high
prevalence and lack of widespread specialist expertise. In
general, a step-wise approach is undertaken, with first-
line conservative treatment, such as lifestyle advice and
laxatives (primary care), followed by conservative bowel
retraining programmes, sometimes including focussed
biofeedback and psychosocial support (secondary/ter-
tiary care). Although these treatments may improve
symptoms in more than half of patients, they are very
poorly standardised and may not improve the whole
range of patient symptoms. The care pathway for nonre-
sponders then separates into two main routes, deter-
mined by local availability of care and clinician
preference: some patients are left to self-manage often
very intrusive symptoms, while others are offered a
range of costly, irreversible surgical interventions with
unpredictable long-term results [17, 18], sometimes
resulting in major adverse events (AEs) or a permanent
stoma.
The current trial forms part of a UK National Institute
of Health Research-funded programme grant (PGfAR:
RP-PG-0612-20001: CapaCiTY). This programme aims
to develop the evidence base for the management of CC
in adults which is currently lacking. This is in contrast
to the management of CC in children for whom UK na-
tional guidance has been published [19, 20]; and for
adults with faecal incontinence [21]. Thus, the current
situation is one where there are considerable variations
in practice, particularly in specialist services. With a
number of new drugs gaining or seeking UK National
Health Service approval [22–25], and potential new
technologies on the horizon [17, 26–28], it is timely that
the currently limited evidence base is developed to pro-
vide confidence that new and sometimes expensive
investigations and therapies are appropriate and cost-
effective. A cost-conscious pathway of care may help to
reduce health care expenditure by appropriately sequen-
cing the care provided, while targeting more expensive
therapies at those most likely to benefit. Such data will
inform the development and commissioning of inte-
grated care pathways.
The CapaCiTY research programme includes a series
of interlinked studies that answer the important ques-
tions for patient care. A rolling programme of national
recruitment will provide a large cohort of well-defined
patients for three studies over 5 years (the present study
plus studies of rectal irrigation and surgery for CC). The
focus will be on generating real-life evidence from prag-
matic studies which will provide valid clinical outcome
measures, and address patient acceptability and cost.
Armed with such data it will be possible to develop a
management algorithm for CC which will meet patient,
clinician and policy aims.
Rationale for choice of comparators
In most UK practices, patients are first referred to a
colorectal specialist for a variety of behavioural
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interventions to improve defaecatory function. A range
of cohort studies [29], randomised controlled trials
(RCTs) [30–35], reviews [36], guidelines [37], meta-
analysis [38] and a Cochrane review [39] attest to the
general success of this approach. However, opinion var-
ies greatly concerning the complexity of intervention re-
quired, which patients are suitable for which
interventions, and UK survey evidence (unpublished
data from our trial development work) indicates that
there is remarkable variability of practice.
The most basic form of behavioural therapy comprises
‘habit training’ (HT). This involves optimising eating
patterns to maximise the gastro-colic response which is
associated with morning clustering of high-amplitude
propagated colonic contractions which propel contents
towards the rectum for subsequent evacuation [40].
Dietary advice to optimise intake of liquid and modifying
intake of wheat, fibre and other elements that the indi-
vidual has found helpful/unhelpful is given, as well as
advice about frequency and length of toilet visits, pos-
ture and how to evacuate effectively without straining.
Patients are also instructed on basic gut anatomy and
function, and gain an appreciation of how psychological
and social stresses may influence gut functioning. Simple
pelvic floor exercises are often included.
More complex forms of therapy include instrument-
based biofeedback learning techniques [29–35].
Favoured in the US, and by about half of UK centres,
these provide direct visual computer-based biofeed-
back of pelvic floor activity, usually displayed as real-
time pressure or electromyogram (EMG) activity
during defaecation manoeuvres (e.g. ‘bearing down’)
or attempted rectal balloon expulsion. It is note-
worthy that most instrument-based programmes have
a one to three sessions/week approach as opposed to
the HT programmes which usually entail less frequent
contact to allow behavioural change to take root.
While small RCTs suggest an additive value of bio-
feedback over HT alone in the management of se-
lected patient subgroups of CC [31, 41–43], there has
been no multicentre or adequately powered RCT in
unselected patients despite uncertain benefit and sig-
nificant resource implications. There is even contro-
versy about which subgroups benefit: some studies
suggest that only those with proven puborectalis inco-
ordination and no slow transit benefit from biofeed-
back [41, 42] while others are less exclusive [29, 31].
Further, most publications advocating biofeedback
have come from specialist centres with considerable
‘investment’ in these techniques with much less
favourable reports when biofeedback is the compara-
tor in a trial of more invasive treatment [44, 45].
These data (and their heterogeneity) have been de-
scribed in a recent Cochrane review [39].
Despite being widely employed, there is conflicting
evidence as to whether radiological and physiological in-
vestigations influence outcomes in CC, with significant
differences of expert opinion. Some advocate early com-
plex and expensive investigations to guide treatment in
most patients [9] whereas others undertake such tests
only in resistant cases or those considering progressing
to surgery [46]. The potential advantage of guiding treat-
ment [42, 47] is balanced against the invasive nature of
some tests, radiation exposure, embarrassment and cost
(circa £600–1200 NHS tariff ): all currently require an es-
calation of care from primary care to hospital, and most
currently necessitate an escalation of care from a sec-
ondary to a tertiary centre. In addition it is not certain
that results are improved by extensive investigation. The
need to resolve this question has been consistently
highlighted [37, 48, 49]. However, it can only be ad-
dressed satisfactorily by evaluating outcomes from treat-
ment with or without these tests. Of particular relevance
is the possibility that specialist-led therapies (as above)
could be stratified using these tests. Notably, there is
some evidence that HT with computer-assisted direct
visual biofeedback (HTBF) may maximally benefit pa-
tients with certain pathophysiologies [35, 41–43, 50, 51],
especially FDD [37, 52, 53].
This protocol has been prepared in accordance with
the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) Checklist and figure
(Additional file 1 and Fig. 1).
Methods/design
Primary objectives
Fig. 1 Standard Protocol Items: Recommendations for Interventional
Trials (SPIRIT) figure
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1. To determine whether standardised specialist-led
HT plus pelvic floor retraining using computer-
assisted direct visual biofeedback (HTBF) is more
clinically effective than standardised specialist-led
habit training alone (HT)
2. To determine whether outcomes of such specialist-
led interventions are improved by stratification to
HTBF or HT based on prior knowledge of anorectal
and colonic pathophysiology using standardised
radio-physiological investigations (INVEST)
Secondary objectives
1. To determine the cost-effectiveness of both inter-
ventions and INVEST
2. To qualitatively evaluate patient and health
professional experience of interventions and
INVEST
Trial design
The study design is a three-arm, parallel-group, multi-
centre RCT. The trial provides two comparisons: HT
(group 1) compared with HTBF (group 2); and
investigation-led treatment (group 3) compared with
management without investigation (groups 1 and 2)
(Fig. 2). Based on our knowledge of the characteristics of
the population we expect approximately 50% of those in
group 3 to be allocated to each of the two treatments to
which individuals are randomised in groups 1 and 2.
Study setting
This trial will be conducted in 10 to 15 UK centres. Pa-
tients attending medical services (primary care through
to specialist centres: outpatient clinics; gastrointestinal
(GI) physiology units) for constipation will be eligible for
recruitment and assessed against the eligibility criteria.
Characteristics of participants
Eligibility criteria
Inclusion criteria
 Age 18–70 years;
 Patient self-reports problematic constipation
Fig. 2 Study design
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 Symptom onset more than 6 months prior to
recruitment
 Symptoms meet American College of
Gastroenterology definition [54] of constipation:
‘unsatisfactory defaecation characterised by
infrequent stool, difficult stool passage or both for at
least previous 3 months’
 Constipation failed treatment to a minimum basic
standard (NHS Map of Medicine 2012 [55] (lifestyle
and dietary measures and at least two laxatives or
prokinetics tried – no time requirement)
 Ability to understand written and spoken English
(due to questionnaire validity)
 Ability and willingness to give informed consent
Exclusion criteria The major causes of secondary con-
stipation and factors precluding participation in study
interventions:
 Significant organic colonic disease (‘red flag’
symptoms, e.g. rectal bleeding prior investigated);
inflammatory bowel disease; megacolon or
megarectum (if diagnosed beforehand); severe
diverticulosis, bowel stricture or birth defects
deemed to contribute to symptoms (incidental
diverticulosis if known is not an exclusion)
 Major colorectal resection surgery
 Current overt pelvic organ prolapse (bladder, uterus,
rectum) or disease requiring obvious surgical
intervention
 Previous pelvic floor surgery to address defaecatory
problems: posterior vaginal repair, stapled rectal
resection (STARR) and rectopexy; previous sacral
nerve stimulation
 Rectal impaction (as defined by digital and
abdominal examination: these form part of the NHS
Map of Medicine basic standard) [55]
 Significant neurological disease deemed to be
causative of constipation, e.g. Parkinson’s disease,
spinal injury, multiple sclerosis, diabetic neuropathy
(not uncomplicated diabetes alone)
 Significant connective tissue disease: scleroderma,
systemic sclerosis and systemic lupus erythematosus
(SLE) (not hypermobility alone)
 Significant medical comorbidities and activity of
daily living impairment (based on the Bartel Index in
apparently frail patients [56, 57]; Barthel Index ≤11)
 Major active psychiatric diagnosis (schizophrenia,
major depressive illness and mania)
 Chronic regular opioid use (at least once daily use)
where this is deemed to be the cause of constipation
based on temporal association of symptoms with
onset of therapy; all regular strong opioid use
 Previous specialist nurse or therapist-led bowel
management
 Severe visual impairment sufficient to prevent visual
biofeedback
 Pregnancy or intention to become pregnant during
study period
Study interventions
Note: all therapists attend a 1-day formal training
event prior to commencing the trial. As part of
intervention fidelity work we are also observing at
least one session per therapist. We have detailed
documents with Standard Operating Procedures
(SOPs) for both the HT and HTBF sessions with
checklists for therapists to complete at the end of
each session so that we can check what has been
covered with each participant. These SOPs are avail-
able from author NS on request. These are all thera-
pists who are delivering biofeedback in routine
clinical practice and in this trial they will all deliver
both interventions.
Group 1: habit training (HT)
Habit training will be provided by trained specialists
(e.g. nurses or physiotherapists) with clinical experience,
who have undertaken an additional study-specific stand-
ard 1-day training session. A standardised approach and
intervention will be provided via use of an intervention
manual; at least one random observation visit will be
performed early in the study by lead research nurses for
quality control.
The course of therapy will include a minimum of
three, maximum of four sessions (45–60 min each
session). This will use a standardised session pro-
forma with an interval tolerance of every 3–5 weeks.
The first and last session will always be face to face.
Sessions will be delivered by the same therapist if at
all possible and tailored to participants’ individual
needs. Each recruiting site will provide sufficient re-
source to cover visits in therapist absence or holiday.
Participants will receive the interventions in Table 1
which are covered in a booklet given to each partici-
pant. The therapist is prohibited from using digital
rectal examination to train manoeuvres and will
complete relevant sections in the participant booklet
advising on individual instructions.
Group 2: habit training plus computer-assisted direct visual
biofeedback (HTBF)
Each session will incorporate all features of the HT
intervention (Table 1), but also include direct visual
biofeedback using a portable high-resolution anal
manometry (HRaM) system and catheter connected to
a laptop computer with large monitor screen (Table 2).
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Calibration, validation and maintenance of the equip-
ment will follow the built-in programme and training
manuals provided and recorded on the system at each
session. Training on the system will be given prior to
sites commencing treatment. Both the patient and the
therapist will be looking at the screen during the
HTBF sessions. We are using state-of-the-art, high-
resolution manometry equipment which displays a
continuous colour display of rectal and anal pressures
in real time. The patient can clearly see if attempted
squeeze or attempted balloon expulsion changes anal
or rectal pressures. The therapist can draw the pa-
tient’s attention to aspects of the display and coach
the patient to improve performance. After each ses-
sion the therapist will note the ability to expel the
balloon, generate propulsion, increase rectal pressure,
relax the anal canal, and the ability to sense the bal-
loon at lower or higher volumes (relevant to hyposen-
sate and hypersensate patients).
Group 3: INVEST – radio-physiology and stratification
(guided treatment)
Radio-physiological investigations Participants allo-
cated to the INVEST arm will undergo standardised in-
vestigations (Table 3) prior to stratification of therapy.
Routine NHS practice will apply in respect of women
between menarche and menopause (that states that
radiological examination, if justified, can be carried
throughout the cycle until a period is missed). Partici-
pants randomised to this group who may potentially be
pregnant will have a pregnancy test performed as per
routine care. The investigations are shown in Table 3.
The results of these investigations will be sent to one
of two designated investigators for analysis. A diagnosis
of ‘functional defaecation disorder’ (FDD) will be made
by assimilation of results from tests in Table 3 by an
agreed protocol based on modified ROME III criteria
[52]. These results will be reviewed centrally by two ex-
pert assessors independently using a secure data-sharing
platform (2-week turnaround).
Modified Rome III criteria Note: the updated ROME
IV criteria were not available at the time of ethical ap-
proval for this study. However, our modified ROME III
criteria take into account all investigative modalities
Table 1 Interventions for habit training (HT – group 1)
a. Provision of a written information leaflet covering normal bowel
function; causes of constipation; diet and fluid advice; getting into a
good bowel habit
b. Review of written information using locally available teaching tools
such as models or diagrams
c. Advice to stop all laxatives including drugs which have a laxative
effect or over the counter herbal teas that contain strong purgatives.
One or two glycerin suppositories are permitted as rescue if no stool
is passed for 3 days. No use of irrigation devices or enemas
d. Encouragement to follow a daily routine: sit on the toilet for 20–30 min
after first meal and/or hot drinks (sooner if urge felt)
e. Advice to attempt defaecation after meals or when urge is felt, but
no more than 3 times per day
f. Advice to sit on toilet with knees bent to 45° position with feet
elevated on stool or equivalent; abdominal brace and breathe while
performing anal relaxation
g. Advice only to attempt to push for 5–10 min maximum
h. Teaching on defaecation manoeuvres, taught while the patient is
positioned sitting on chair with verbal coaching to breathe while
pushing
i. Strong discouragement from multiple attempts and prolonged straining
j. Advice not to digitate anally
k. Where appropriate, the participant will be taught rectocoele (vaginal),
perineal and perianal splinting;
l. Therapist prohibited from using digital rectal exam to train
manoeuvres
m. Diet and lifestyle advice, e.g. moderate but not excessive fibre;
moderate but not excessive fluid intake; increase physical exercise,
e.g. walking if possible
n. Participants with evacuation difficulty and/or perineal descent will be
taught pelvic floor exercises
o. Plenty of optimism, encouragement and personal attention
p. Suggestions of what to work on until next intervention session
q. Therapist to complete relevant sections of patient booklet
Table 2 Additional interventions at each session for group 2
a. Biofeedback balloon and catheter/probe will be connected to the
manometry system and linked to the computer monitor. Patient lying
in lateral position facing computer screen (supine if unable to lie in
lateral position). Probe taped or held into position
b. Resting and squeeze pressure noted
c. Rectal balloon inflated with air at 2 mL/s to assess first sensation, urge
sensation and maximum volume tolerated. Volumes noted. Maximum
fill to 360 mL
d. Recto-anal inhibitory reflex (RAIR) elicited with 50-mL aliquots using
rapid balloon inflation with air at 30 mL/s. Volume to first urge and ef-
fect on resting pressure noted, maximum 150 mL
e. Participant will receive coaching to evacuate with 60 mL water (one
syringe full) in the balloon. Participant will attempt balloon expulsion
while the effect on anal pressure is noted
f. The therapist will monitor attempts to relax while pushing and
attempting to expel the balloon. Instruct participant to push and
breathe, emphasising the need to push from the waist while relaxing
the anus. Note propulsive effort. A minimum of 3 and no more than
10 attempts in total, with coaching (therapist observes abdominal and
anal activity and advises), or until balloon is expelled (not essential).
Therapist will advise on correct pushing technique
g. High-resolution anal manometry (HRaM) can also be used to coach
pelvic floor exercises if indicated (e.g. evident perineal descent on
pushing)
h. Participants undergoing biofeedback may have rectal hypersensitivity
or hyposensitivity. At each interventional visit, these participants will
undergo sensitivity training. The goal will be to increase
(hypersensitive) or decrease (hyposensitive) tolerated balloon volume
by gentle progressive distension or progressively lower volume of air
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(manometry, balloon expulsion and proctography: as
Rome IV), and state:
Subjects must have, during repeated attempts to defae-
cate, evidence of impaired evacuation, based on either:
1. Failed balloon expulsion test, and/or
2. Impaired evacuation on proctography (failure to
expel 65% contrast in 150 s),
with or without at least one of the following:
Inappropriate contraction of the pelvic floor or less
than 20% relaxation basal anal pressure on push
manoeuvre (manometry) or proctographic evidence of
failed puborectalis relaxation or paradoxical
contraction; inadequate expulsive forces assessed by
manometry or proctography.
Abnormal pattern of anorectal manometry is defined as
inappropriate contraction of pelvic floor or less than
20% relaxation basal anal pressure on push manoeuvre
and/or inadequate expulsive forces.
Based on the results of these investigations, participants
diagnosed with FDD will undergo HTBF as above
(group-2 interventions). Those without FDD will
undergo HT only (group-1 interventions).
The distribution of stratification factors in group 3,
based on modified criteria for FDD [52], are met by
approximately 50% of adult patients with CC based on
UK data, and thus will be balanced in comparison with
patients not receiving investigations. The allocation
ratio will be monitored by the Data Monitoring
Committee (DMC) (see below).
All three groups: concomitant care
Telephone support will be available from the therapist
between visits (telephone number given, office hours
only). In the instance of new psychological issues being
determined during consultation, referral for psycho-
logical support will be deferred until after completion of
behavioural interventions, except where there is clinical
concern regarding the participant’s acute mental state
requiring more urgent intervention (see below: with-
drawal from treatment criteria).
Laxative use
All participants will be asked to discontinue laxative use
at the first intervention visit and to refrain from using
laxatives throughout the trial, as is standard UK practice
in specialist biofeedback services. However, it is inevit-
able that participants will seek recourse to laxatives and
other dietary supplements during the course of the
programme. Experience shows that complete prohibition
can lead to unreported laxative use, which might con-
found findings. Although we will strongly discourage ad
libitum medication usage and specify a defined break-
through regimen, we will record co-treatment with suffi-
cient fidelity and integrity to enable use as covariates in
analyses using a specific journal for this purpose (within
the patient journal: see ‘Study Outcome Measures’). A
concomitant medications list, including a shortlist of
contributory or confounding medications, will be used
to filter on data entry.
Withdrawal criteria
Individual participants may be withdrawn from treat-
ment in any of the following circumstances:
 Becomes pregnant or intends to become pregnant
(only in baseline and intervention phases)
 Subsequently diagnosed with proven cause for
secondary constipation, e.g. Parkinson’s disease or
bowel obstruction
 Requires new medication with proven effects on
bowel function, e.g. opioids
 Develops significant intercurrent illness precluding
participation
 Requires surgery or other intervention (other than
minor operations) during treatment phase
Table 3 Investigations received by participants in group 3
(INVEST)
a. Anorectal manometry using high-resolution methods [80–82] will be
used to determine defined abnormalities of recto-anal pressure gradient
(see above for definition of functional defaecation disorder (FDD)) during
simulated evacuation [37, 83, 84]. A standard high-resolution anal
manometry (HRaM) system will be used with a standard laptop.
Calibration, validation and maintenance of the equipment will
follow the built-in programme and training manuals provided and
will be recorded on the system at each session. Training on the
system will be performed and documented in the investigator site file
prior to sites commencing treatment
b. Balloon sensory testing using standardised methods [85, 86] (2 mL air
per second to maximum 360 mL) will be used to determine volume
inflated to first constant sensation, defaecatory desire and maximum
tolerated volumes. Rectal hyposensation and hypersensation will be
defined in accord to gender-specific normative data on 91 healthy
adults [87]. The recto-anal inhibitory reflex will also be elicited by
50 mL rapid inflation (if necessary in 50-mL aliquots up to 150 mL)
c. A fixed-volume (50 mL) water-filled rectal balloon expulsion test
[37, 70, 83] will be conducted in the seated position on a com-
mode. Abnormal expulsion is defined as failure to expel with a 1-
min effort for men and 1.5 min for women [88]
d. Whole gut transit study will use serial (different shaped) radio-opaque
markers over 3 days with single plain radiograph at 120 h [89–91]
e. Fluoroscopic evacuation proctography will use rectal installation of
barium porridge to defaecatory desire threshold (or maximum
300 mL) and evacuation on a radiolucent commode [90, 92–95] with
preopacification of the small bowel (for enterocoele). Radiation dose,
proportion of contrast evacuated and time taken will be recorded, as
well as ‘functional’ (i.e. pelvic floor dyssynergia) and ‘structural’
features deemed obstructive to defaecation (e.g. rectocoele,
enterocoele and intussusception) [37, 87, 96]. There is a maximum
fluoroscopic screening time of 3 min
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 Develops acute psychological problem causing safety
concern
 Elective withdrawal
All data collected up to the point of withdrawal from
treatment will be used in the analyses and data will be
collected at further time points unless participants spe-
cifically request otherwise. Participants may also request,
at any point, no further follow-up visits or data
collection.
Strategies to improve adherence
Participants will be thoroughly counselled from the out-
set, detailing the study requirements and number of
face-to-face treatment visits, the type and nature of all
procedures and follow-up data collection visits, includ-
ing all time commitments and responsibilities when tak-
ing part in the study. This will help to improve
compliance with the protocol. Additional strategies to
improve compliance include a visit window and toler-
ance of ±1 week and allowance for missing one of four
treatment visits, and a follow-up time frame of 6 months
without recourse to additional treatments to ensure the
primary outcome remains uncontaminated. The partici-
pants may then move on to alternative treatments within
the NHS routine care pathway or studies 2 or 3 within
the CapaCiTY programme. Further strategies include re-
imbursement for patient travel at study milestones in-
cluding baseline, 6-month and 12-month follow-up
visits.
Study outcome measures
Clinical endpoints
We have adopted a standardised outcome framework
throughout the CapaCiTY programme. A set of standard
clinical endpoints will be reported in this and the other
studies that are part of the programme.
Primary clinical endpoint
Self-reported at 6 months after end of intervention:
Response to treatment defined as reduction in the
Patient Assessment of Constipation–Quality of Life
(PAC-QOL) score (Table 4) of at least 0.4 points [58–60].
Secondary clinical endpoints
Self-reported at baseline and at 3, 6 and 12 months after
end of intervention:
 Responses to treatment defined as a reduction in
PAC-QOL score of at least 0.4 point [58–60]
 Binary responses to treatment defined as either a
1-point (or greater) reduction in PAC-QOL score
[58–60]
 PAC-QOL: individual domains and total score (as
continuous variables)
 Patient Assessment of Constipation–Symptoms
(PAC-SYM) score [61]: individual domains and total
score (as continuous variables)
 A 2-week patient diary (for 2 weeks prior to each as-
sessment) to record bowel frequency and whether
each evacuation was ‘spontaneous (no use of laxa-
tives) and/or complete’; journal will also capture
concurrent medication, health contacts, time away
from normal activities (including work) since the pa-
tient’s last visit
 Generic quality of life: the EuroQol Health Outcome
Measure (EQ-5D-5 L) [62] descriptive system and
the EuroQol Visual Analogue Scale (EQ-VAS) [63]
 NHS resource use: interventions, treatment sequelae
and other health resource use related to the care of
CC
 Patient costs related to constipation and the
opportunity cost of time away from normal activities
 Patient Health Questionnaire-9 (PHQ-9) [64, 65]
 Generalised Anxiety Disorder Questionnaire (GAD-7)
[66]
 Global study-specific patient satisfaction/improve-
ment score (Visual Analogue Scale: VAS) and
whether they would recommend each treatment
experienced to other patients
 Potentially modifiable cognitive and behavioural
psychological variables shown to predict onset and
perpetuation of other functional bowel symptoms:
negative perfectionism [67], avoidant and ‘all or
nothing’ behaviour subscales of the Behavioural
Response to Illness Questionnaire [68] (CC-BRQ),
and the Brief Illness Perception Questionnaire
(BIPQ (CC)) [69]
A copy of trial outcome measures is available from the
trial manager on request.
Participant timeline
The study flow chart is shown in Fig. 2.
Study visits
Visit 0: prescreening: eligibility assessment Patients
referred from primary care or identified in secondary or
tertiary care clinics will be approached by a suitably
trained and delegated local researcher who will screen
for basic eligibility by telephone or face-to-face interview
(based on patient choice) on the basis of a simplified in-
clusion/exclusion criteria proforma (i.e. self-reported
constipation for more than 6 months, difficulty passing
stool and/or infrequent passing of stool, at least two
medications tried for relief of symptoms). Patients will
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Table 4 Primary endpoint the Patient Assessment of Constipation–Quality of Life (PAC-QOL) score
The following questions are designed to measure the impact that constipation has had on your daily life over the past 2 weeks. For each question, please
check one box.
Not at all
- 1
A little bit
- 2
Moderately
- 3
Quite a bit
- 4
Extremely
- 5
The following questions ask about your symptoms related to constipation. During
the past 2 weeks, to what extent or intensity have you…
1. Felt bloated to the point of bursting?
2. Felt heavy because of your constipation?
The next few questions ask about how constipation affects your daily life. During
the past 2 weeks, how much of the time have you…
3. Felt any physical discomfort?
4. Felt the need to have a bowel movement but not been able to?
5. Been embarrassed to be with other people?
6. Been eating less and less because of not being able to have bowel movements?
The next few questions ask about how constipation affects your daily life. During the
past 2 weeks, to what extent or intensity have you…
7. Had to be careful about what you eat?
8. Had a decreased appetite?
9. Been worried about not being able to choose what you eat (for example, at a friend’s
house)?
10. Been embarrassed about staying in the bathroom for so long when you were away
from home?
11. Been embarrassed about having to go to the bathroom so often when you were
away from home?
12. Been worried about having to change your daily routine (for example, traveling,
being away from home)?
The next few questions ask about your feelings related to constipation. During the past
2 weeks, how much of the time have you…
13. Felt irritable because of your condition?
14. Been upset by your condition?
15. Felt obsessed by your condition?
16. Felt stressed by your condition?
17. Felt less self-confident because of your condition?
18. Felt in control of your situation?
The next questions ask about your feelings related to constipation. During the past
2 weeks, to what extent or intensity have you…
19. Been worried about not knowing when you are going to be able to have a bowel
movement?
20. Been worried about not being able to have a bowel movement?
21. Been increasingly bothered by not being able to have a bowel movement?
The next questions ask about your life with constipation. During the past 2 weeks,
how much of the time have you…
22. Been worried that your condition will get worse?
23. Felt that your body was not working properly?
24. Had fewer bowel movements than you would like?
The next questions ask about your degree of satisfaction related to constipation. During
the past 2 weeks, to what extent or intensity have you been…
25. Satisfied with how often you have a bowel movement?
26. Satisfied with the regularity of your bowel movements?
27. Satisfied with the time it takes for food to pass through the intestines?
28. Satisfied with your treatment?
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be recorded on a screening log and each will be allo-
cated a sequential trial screening number. Patients will
be provided with adequate explanation of the aims,
methods, anticipated benefits and risks of the relevant
interventions and will take away or be posted an invita-
tion letter and a Patient Information Sheet. Patients will
be given at least 24 h to consider participation and in-
vited to attend clinic for a more detailed discussion with
a suitably trained researcher. The simplified criteria will
be used in marketing and promotional materials and will
be made available on the study websites with the Partici-
pant Information Sheet for patients to self-screen. Those
responding to marketing and promotion of the study will
be prescreened by the national coordinating centre and
referred to their nearest participating trust.
Visit 1: screening, consent and baseline assessments
Visit 1 will be conducted face-to-face in clinic. Following
a detailed discussion about the trial, eligible and agree-
able patients will complete written informed consent.
Screening and confirmation of eligibility will be followed
by standardised medical and surgical history by inter-
view including previous medication usage. Clinical
examination findings (carried forward if performed pre-
viously within last 3 months) and standardised examin-
ation of the perineum/anus/rectum/vagina will be
performed.
Baseline assessments include several key validated as-
sessments that profile patients for important characteris-
tics informing disease pathophysiology and important
potential predictors of treatment response. This includes
the constipation and irritable bowel syndrome modules
of the Rome III questionnaire [70], the Cleveland Clinic
Constipation Score Questionnaire [71], brief chronic
pain, autonomic symptoms [72] and joint hypermobility
[73] assessments and St. Mark’s Faecal Incontinence
Score [74]. All were selected on the basis of trade-off be-
tween adequate detail and brevity. These instruments
have been collated into a single booklet with design and
presentation optimised by patient representatives. Partic-
ipants will complete the questionnaire booklet (contain-
ing baseline, primary and secondary outcomes listed
above), and be given a baseline 2-week patient diary and
journal. All participants will be asked to complete the 2-
week patient diary prior to INVEST, HT or HTBF inter-
ventions and prior to stopping laxatives.
Urinary pregnancy testing will be made available to
women of child-bearing potential at eligibility assess-
ment and advice will be given to all women regarding
the need to prevent pregnancy during the study inter-
vention period. Randomisation to HT-, HTBF- or
INVEST-guided intervention will be completed at the
end of visit 1.
Visits 2–5: interventions Participants randomised to
treatment without INVEST will undergo four sessions of
standardised therapy (HT or HTBF) (Tables 1 and 2).
Those randomised to INVEST will have additional
radio-physiological investigations (Table 3) prior to be-
ing stratified to receive either HT or HTBF. A review of
all related AEs and changes in confounding medications
will be conducted at each intervention visit.
Visits 6–8: follow-up outcome assessments (3, 6 and
12 months) The standardised outcome questionnaires
booklet will be completed and the 2-week Bowel Diary
and Patient Journal completed and returned, including a
review of all related AEs and changes in confounding
medications. In order to maximise completeness of data
collected, the 3- and 6-month follow-up visits will be
conducted face to face wherever possible. Follow-up at
12 months can, however, be conducted by telephone.
The 6-month time point at which the primary outcome
is recorded will coincide with the end of a protocol-
imposed ‘quarantine’ period during which a participant’s
response to therapy will remain unconfounded by treat-
ment progression.
Sample size for the trial
The sample size has been calculated using the primary
clinical outcome change in PAC-QOL score. A 0.4-point
(10% of scale) reduction in PAC-QOL score [75–77]
with a variance estimate conservatively set at a standard
deviation (SD) = 1 will be considered clinically relevant.
To detect a mean change of 0.4 in PAC-QOL score
(SD = 1) with 90% power and 5% significance level, 132
per arm or 264 participants in total will be required for
the comparison of HT and HTBF (No-INVEST arm).
For the secondary comparison of INVEST versus No-
INVEST a reduction of 0.4 points (SD = 1) will also be
considered clinically meaningful. To detect an effect size
of 0.4 with 90% power and at 5% significance level re-
quires 90 participants in the INVEST arm assuming 264
participants have been recruited to the No-INVEST arm.
Allowing for a 10% loss to follow-up, a sample size of
147 is needed in the HT and HTBF arms and 100 in the
INVEST arm. A total sample size of 394 patients across
the three arms is required.
Recruitment
All recruiting sites have been chosen based on feasibility
assessments and ability to recruit the required number
of participants during the recruitment time frame. An
assessment of competing studies, research experience
and required resources to conduct the study was also
undertaken to ensure that targets can be achieved. The
recruitment rates at each site will be monitored through-
out the course of the study and barriers to recruitment
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identified and addressed as they arise. Reserve sites have
been identified to address any shortfalls in recruitment.
If a larger than anticipated dropout rate occurs, it will be
possible to recruit further patients above that suggested
in each arm to maintain study power.
Assignment for interventions
Sequence generation and allocation
Randomisation sequence will be computer-generated.
Randomisation will take place after consent, eligibility
and baseline assessments. We will use a secure, online,
access-controlled randomisation system managed by the
UKCRC registered, Barts and the London, Pragmatic
Clinical Trials Unit (PCTU).
Stratification for therapy
As for previous studies in this area we expect to recruit
very few men. To ensure balanced randomisation within
gender, and secondarily within centres, randomisation
will be stratified by gender and then women by centre.
Allocation concealment mechanism
The randomisation system is user-access-controlled to
maintain allocation concealment from blinded
individuals.
Blinding
Patients and clinicians are necessarily aware of both IN-
VEST and treatment allocations after randomisation.
The primary outcome and several other outcomes are
self-reported. All those involved in developing the statis-
tical analysis plan will be blinded to allocation status
until the plan is signed off, and no analyses of outcomes
will be undertaken until that is done. To minimise ob-
server bias, a blinded researcher will collect outcome
data. If a blinded researcher is unavailable, the primary
outcome questionnaire will be completed by the partici-
pant without assistance and secured in an envelope.
Statisticians performing the analysis will remain
blinded.
Data collection, management and analysis
Data collection
Data collection methods consist of a mixture of routine
clinical data collected by investigators and patient-
reported outcomes. Validated questionnaires have been
chosen for the majority of the primary and secondary
outcome measures, with the exception of the Patient
Bowel Diary and Health Utilisation Journal. All partici-
pants will be trained in completing the questionnaires at
baseline, prior to randomisation and will be provided
with a standardised guideline for completing question-
naires to minimise errors or missing data. When avail-
able, a blinded outcome assessor will check to verify and
confirm questionnaire completion. In order to minimise
missing data, follow-up visits up to 6 months post treat-
ment will be conducted face to face. Thereafter, data can
be collected over the telephone or via mail). All data will
be collected on intention-to-treat principles regardless
of protocol excursions and deviations or withdrawal
from trial treatments. At least three attempts via two dif-
ferent methods (e.g. telephone and letter), will be made
by research staff to make contact and collect follow-up
data, after which the participant may be considered lost
to follow-up. Participants may be lost to follow-up in the
following circumstances:
 After at least three failed attempts by research staff
to make contact via two different methods (e.g.
telephone and letter)
 Participant does not wish to participate in follow-up
data collection
 Death or significant incapacity making follow-up
data collection impossible
A copy of all Data Collection Forms is available from
the trial manager on request
Data management
Each recruiting site will be required to keep accurate
and verifiable source notes in the medical record rele-
vant to each study participant’s inclusion and continued
participation in the study.
Data will be collected, transferred and stored in ac-
cordance with Good Clinical Practice (GCP) guidelines
and data protection requirements. The PCTU SOPs and
study data management plan and SOP will define the
exact process of data collection, transfer, storage and
quality control of study data.
A secure online trial database will be provided by the
PCTU to enable remote data entry at sites where this is
feasible. This database will provide built-in data valid-
ation range checks. Additional quality control will be
performed by the central study team on the study data
prior to review by the DMC and statistician. These
checks will consist of:
a. Repeating data entry (into a separate data table/
database provided by the data manager) for a
random sample, 10% of the baseline and final
outcome data and comparing it with the main
database. Discrepancies will be checked against the
Case Report Form (CRF) to ensure data entry errors
on validation are not counted and only those errors
that occurred within the main database will be
counted. These errors will be cleaned and corrected
b. Values for each variable will be sorted by the
statistician, and those at the extremes will be
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checked to ensure that they are either correct or
within the expected range
Error rates of 1% for primary outcomes and 3% for the
remaining data will need to be achieved. The error rate
(r) will be calculated by comparing the number of errors
(e) with the total number of CRF fields (t): r (%) = (e/t) ×
100. If the prespecified error rates are not achieved, data
checking and cleaning will be repeated (in additional
random 10% lots) and continue until the error rate is
met. Missing data will be handled according to the stat-
istical analysis plan. In addition on-site monitoring will
enable source document verification of records and will
follow the PCTU trial monitoring SOPs and the trial
monitoring plan.
All patient-identifiable data, such as Consent Forms,
screening and identification logs will be stored in the in-
vestigator site files in secure, locked cabinets and offices,
accessible only to delegated members of the study team.
Secure methods of data transfer will be used to return
CRFs to the coordinating site for centralised data entry,
monitoring, quality control and in compliance with
GCP. A copy of the CRF is held at the site in accordance
with GCP.
Statistical methods
Clinical outcomes analysis
The primary outcome will be analysed on intention-to-
treat at the 6-month time point (prior to progressing to
further condition-specific care). The average reduction
in PAC-QOL score will be analysed using linear mixed-
model regression with a random effect for centre and
fixed effects for intervention, gender, baseline PAC-QOL
and breakthrough medication.
Secondary outcomes will be analysed at 6-months and
at additional time points (3 and 12 months from end of
treatment) including the percentage of patients achiev-
ing a 1-point reduction. Outcomes will take the form of
count (change in number of symptom episodes), ordinal
(patient’s global impression of success) and continuous
(questionnaire scores) data. Regression models, with a
random effect for centre, appropriate to the outcome
data types will be fitted to estimate the treatment effect,
adjusting for baseline values (when appropriate), gender,
and breakthrough medication use as a potential
confounder.
Predictive modelling using baseline characteristics:
measures of chronic pain, autonomic symptoms, joint
hypermobility, cognitive, behavioural and mood variables
share the common hypothesis that they are detrimental
to the success of all treatments, i.e. they perpetuate ill-
ness in spite of therapy. Appropriate regression models
will be developed to determine the influence of these
pretreatment characteristics on the success of
treatments.
Analysis will be performed using proprietary software
(Stata, Stata Corp., College Station, TX, USA) by the
appointed study statistician. P < 0.05 will be taken to in-
dicate statistical significance. No analyses will be con-
ducted until a statistical analysis plan (SAP) has been
written and reviewed by an independent statistician. The
SAP will be approved by the senior statistician and chief
investigator. Multiple imputation will be used to address
missing values. Subgroup analyses will be performed for
selected baseline characteristics.
Health economic outcome analysis
The pragmatic multicentre trial design reflects real-
world clinical practice, thus cost and outcome profiles
are likely to reflect routine care in NHS settings. Individ-
ual patient data collected within the trial included NHS
treatment and personal costs as well as health status es-
timated as quality-adjusted life years (QALYs). Cost-
effectiveness analysis will capture the effect of treatment
as changes in cost and QALYs. The base case analysis
will proceed using multiple imputation of patient data to
manage missing values, following good practice guidance
[78, 79]. Imputed datasets will be analysed independently
and the estimates obtained will be pooled to generate
mean and variance estimates of costs and QALYs using
Rubin’s rule [75]. Each analysis will use a bivariate re-
gression modelling approach to capture the correlation
of costs and outcomes as well as covariates within each
model. Models will be bootstrapped with 5000 replicates,
using Stata. Supportive sensitivity analyses, including
complete case analysis, will be used to explore the im-
pact of imputation and missing data.
Cost-effectiveness models that extrapolate beyond 3–6
months’ duration are problematic in adult constipation,
as outcomes are contingent upon subsequent care re-
ceived and the underlying disease process. However, the
programme of work packages provides a unique oppor-
tunity to construct probabilistic models exploring opti-
mal pathways from effectiveness and cost-effectiveness
perspectives. Since patients will (within the CapaCiTY
programme) be followed along a pathway that includes a
series of steps of care, it will be possible to construct
costs and outcomes for a range of patient pathways pro-
viding comparative longer-term cost-effectiveness esti-
mates. For example, it will be possible to ask whether
INVEST or No-INVEST-led first-line care leads to lower
overall costs or improved outcomes. For the overall
CapaCiTY programme of studies, patient-level data from
recruitment through the various work packages will be
used to construct pragmatic, probabilistic models to ex-
plore optimal pathways from effectiveness and cost-
effectiveness perspectives.
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Since EQ-5D and EQ-VAS typically have SDs of 30%
of scale: a 10% difference deemed clinically significant
can be detected with the large sample sizes proposed
within the trial. Adjustment for time preference will be
at the socially accepted rate for cost-effectiveness ana-
lyses (currently 3.5% for costs and benefits). Patient use
of resources and EQ-5D values will be used to estimate
the cost-effectiveness of the three comparisons being
studied. A base case analysis will estimate within trial in-
cremental cost/quality-adjusted life years (QALYs)
gained from an NHS perspective, with missing values
imputed and with adjustment for trial covariates. A
range of supportive sensitivity analyses will include a
complete case analysis, effect of covariate adjustment
and analysis perspective.
Nested qualitative study: patient and health professional
experience
Face-to-face, semistructured interviews will be con-
ducted involving a diverse sample of patients and profes-
sionals purposefully selected at various time points
throughout the study:
1. Before starting to gauge expectations
2. During treatment to explore fidelity and ease of
adherence
3. Immediately after, and up to 2 years after,
intervention, to explore perspectives on the
intervention and longevity of any benefit and pattern
of response over time
Participants for interview will be selected from a sam-
pling grid of potential interviewees from all three arms,
both improved and not improved by intervention, to re-
flect a range of ages, geographical locations and, where
possible, other pertinent attributes such as ethnicity and
gender. Approximately 50 interviews (or until apparent
data saturation) will be conducted with participants. We
will also interview 10 professionals delivering the inter-
vention, to determine comparative ease of delivery of the
two interventions.
Separate informed consent will be taken for interviews
(see Additional file 2 for Consent Form). Interviews will
be conducted throughout to capture relatively early and
later experiences and perceptions of the interventions. A
topic guide for the interviews, informed by the existing
literature and our patient advisors, has been developed.
Qualitative analysis
Interviews will be digitally recorded, anonymised, tran-
scribed verbatim and analysed using a pragmatic the-
matic analysis and NVivo8 software (QSR International
Ltd., Warrington, UK) for data management. Data ana-
lysis will be developed as outlined by Fereday and
Muir-Cochrane [78] in the first instance by mapping
key concepts derived from the transcripts (‘charting’)
and extracting emergent themes from the transcripts.
A second researcher will conduct independent ana-
lyses and then compare and refine resulting codes
and themes in discussion. Emergent themes, together
with captured observational data, will form the basis
of analytical interpretation.
Monitoring and audit
The PCTU quality assurance manager will conduct a
study risk assessment in collaboration with the CI. Based
on the risk assessment, an appropriate study monitoring
and auditing plan will be produced according to PCTU
SOPs. This monitoring plan will be discussed and
authorised by the sponsor before implementation. Any
changes to the monitoring plan must be agreed by the
PCTU quality assurance manager and the sponsor. Au-
dits may be conducted by the sponsor or funder repre-
sentative. The study may be identified for audit via the
risk assessment process, investigator or department re-
quest, allegation of research misconduct or fraud or a
suspected breach of regulations or selected at random.
Trial committees
The trial and the whole CapaCiTY programme will be
overseen by a Programme Steering Committee (PSC).
The role of the PSC is to provide overall supervision of
the study on behalf of the sponsor and funder to ensure
that the study is conducted in accordance with the prin-
ciples of GCP and relevant regulations.
The responsibilities of the PSC will include: ensuring
that views of users and carers are taken into consider-
ation; advising on the trial protocol; advising on changes
in the protocol based on considerations of feasibility and
practicability; assisting in resolving problems brought to
it by the Programme Management Group (PMG); moni-
toring the progress of the trial and adherence to proto-
col and milestones; considering new information of
relevance from other sources; considering and acting on
the recommendations of the Data Monitoring and Ethics
Committee (DMEC), sponsor and/or Research Ethics
Committee (REC); reviewing trial reports and papers for
publication.
The PMG will meet monthly initially during study set-
up and then every 2 months. The PMG will be respon-
sible for day-to-day project delivery across participating
centres, and will report to the PSC.
The DMEC will meet at least 4 weeks prior to the PSC
to enable recommendations to be fed forward. The
DMEC will comprise an independent chair an independ-
ent statistician and a clinician.
A Constipation Research Advisory Group (CRAG) will
comprise eight patients and two lay members. This
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group will have geographical diversity and a disease-
appropriate demographic (eight women, two men). The
CRAG will be involved in review of participant informa-
tion sheets, booklets, diaries and advertising/marketing
materials, project management by representation on the
PSC, parallel qualitative analysis, dissemination of results
and lay summaries, and presentations at local research
events.
There are no plans for interim analysis as this is a low-
risk study.
Harms
The risks arising from participation are considered very
low. The interventions proposed are those already of-
fered to patients in specialist centres throughout the UK
and internationally. The only difference conferred by
participation is that these interventions will be randomly
allocated and more carefully assessed. All interventions
are safe. For instance, the only invasive tests (INVEST)
have been performed daily in most specialist centres for
up to 30 years without any recorded complication (ex-
perience of the lead centre is more than 122,000 pa-
tients). A small ionising radiation dose is required for
two tests. All devices used in the study are CE-marked
and will be used in accordance with manufacturer’s in-
structions and intended uses.
A number of questionnaires contain personal ques-
tions about bowel problems and the effect of these on
quality of life and psycho-behavioural functioning; how-
ever, all have been used in studies of similar patients
previously.
The benefits of participation are that patients will re-
ceive a very high standard of monitored care as a conse-
quence of the detailed protocol. In some instances
(geographically), patients may receive interventions for
which they did not previously have access.
There are minimal safety considerations attributable to
the interventions. Patients allocated to INVEST-guided
therapy will undergo two radiological procedures (whole
gut transit study and evacuation proctography) using
ionising radiation as outlined above. The combined dose
of these procedures (approximately 1.2 mSv) is equiva-
lent to less than 7 months’ annual background radiation
dose from living in the UK. Further, these investigations
would be carried out in routine clinical practice in many
centres for patients at the same point as recruitment to
this study. There are rare reports of local irritation or
discomfort subsequent to manometry and very rare re-
ports of rectal perforation after manometry [79], but
only in the presence of prior radiotherapy and surgery.
As no medicinal products are being administered as
part of the trial and all trial interventions are as per the
standard care provided within the NHS for chronic con-
stipation, unrelated AEs will not be recorded on the
CRF. Causality will be at the discretion of the health care
provider. Serious adverse events (SAEs) will be recorded
on the CRF and in the medical notes to enable assess-
ment and reporting in line with sponsor and regulatory
requirements.
Trial participants will be advised to seek medical sup-
port from their family physician for any unrelated signs,
symptoms or disease or aggravation of underlying
symptoms.
SAEs that are considered to be ‘related’ and ‘unex-
pected’ are to be reported to the chief investigator and
sponsor within 24 h of the site learning of the event and
by the coordinating team to the REC within 15 days in
line with the required time frame.
The following SAEs are expected to occur rarely in
this patient population and will not be reported:
 Hospital admission for exacerbation of constipation
symptoms including impaction
 Hospital admission for unrelated elective surgical
procedures or accidental injury
In the event that participants suffer harm during the
research study, and this is due to someone’s negligence,
then participants may have grounds for legal action
against the sponsor Queen Mary University of London.
Insurance and indemnity is provided by the sponsor to
cover such claims.
Criteria for discontinuation
The interventions proposed are well-established in
current clinical practice and have minimal safety con-
cerns. There are no defined criteria for discontinuation.
Additionally, if the DMEC, PSC, REC or sponsor deter-
mine that it is within the best interests of the partici-
pants or trial to terminate the study, written notification
will be given to the chief investigator. This may be due
to, but not limited to, safety concerns, proof of effective-
ness or serious and persistence noncompliance/serious
breaches. If the study is terminated, participants will be
returned to the NHS for normal follow-up and routine
care.
Ethical issues
Confidentiality
Information related to participants will be kept confi-
dential and managed in accordance with the Data Pro-
tection Act, NHS Caldecott Principles, The Research
Governance Framework for Health and Social Care, and
the conditions of REC approval. All CRFs will be pseu-
donymised. The participant’s GP will be informed of
their participation in the study.
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Access to data
All authors of the final trial report will have full access
to data with no restrictions. Trial records will be ar-
chived for a period of 20 years.
Post-trial care
Participants who do not achieve what they consider to
be adequate relief of symptoms following trial comple-
tion will be referred back to the NHS pathway of care
and considered by the local clinical team for further
care. They may be offered biofeedback if this has not
already performed within the study or be eligible to pro-
gress to other work packages in the CapaCiTY
programme (rectal irrigation and consideration for lap-
aroscopic ventral mesh rectopexy surgery). Alternatively,
they may be offered these or other treatments outside
the study.
Dissemination
Results of the trial will be prepared for presentation at
relevant scientific meetings and submitted to a leading sci-
entific journal for publication. All protocol authors meet-
ing journal criteria will be eligible as authors of these
works and no professional writers will be utilised. With
our patient representatives we will prepare a lay summary
for the public. The results will also feed into the develop-
ment of a care pathway for chronic constipation as part of
the wider CapaCiTY programme grant. We have no plans
to make the dataset publically available.
Discussion
This trial has the potential to answer some of the major
outstanding questions in the management of the com-
mon problem of chronic constipation which is resistant
to primary care interventions. It should enable decisions
about whether costly invasive tests are warranted prior
to specialist management and whether computer-
assisted biofeedback confers additional benefit to well-
managed conservative specialist advice alone.
Trial registration
The trial is registered on a publically accessible registry:
ISRCTN11791740 (date of registration 16 July 2015);
http://www.isrctn.com/ISRCTN11791740.
Trial status
The trial commenced recruitment in March 2015 and
will take 30 months to recruit 394 patients. Recruitment
milestones will be closely monitored.
Contacts
For scientific enquiries: CI: Professor Charles Knowles:
c.h.knowles@qmul.ac.uk.
For public and administrative enquiries: trial manager:
Natasha Stevens: n.stevens@qmul.ac.uk.
Additional files
Additional file 1: SPIRIT Checklist. (DOC 121 kb)
Additional file 2: Study Consent Form. (DOCX 47 kb)
Additional file 3: Consent form for interviews. (DOCX 48 kb)
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